Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
about
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.The role of dextromethorphan in pain control.New treatments for the motor symptoms of Parkinson's disease.Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.Striatal glutamatergic mechanisms and extrapyramidal movement disorders.Other pharmacological treatments for motor complications and dyskinesias.Novel pharmacological strategies for motor complications in Parkinson's disease.Nondopaminergic mechanisms in levodopa-induced dyskinesia.New therapeutic approaches to Parkinson's disease including neural transplants.Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersLevodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.Mechanisms of disease: basic-research-driven investigations in humans--the case of hyperkinetic disorders.Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsEmerging drugs for levodopa-induced dyskinesia.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsGlutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
P2860
Q32052308-DAD15027-2BAA-4FA2-8CFA-8E4CBACE349FQ33956193-D02AB95E-2921-4424-AE07-E0B608BEE2B4Q34443682-B20CE5E4-A3AA-499C-A81A-6579F7E94EC3Q34446551-EDD94293-BEAB-43F8-AB8E-A4A3CDC2F25AQ34532735-E636830B-26F6-4C0E-86A9-A4A910F269C2Q35165439-447414DD-4799-4CC0-9028-44C3005B087AQ36094528-2A37CF70-5166-49BC-A283-FFB3C17341D3Q36120761-0DF6CC37-BA67-4D76-8117-262DAC04ED72Q36188913-B1668AEE-2235-4FA0-BA1C-85DBE7FF8BA4Q36225073-FE975DD5-AD11-4AB6-B053-96B0F748C6DFQ36549794-179164B6-977D-4269-9BC0-D3543BB09E71Q36799584-9A2C730F-F670-4B3E-971A-7E882F98CB7FQ36873506-EE7930E2-B76E-4367-B813-E31258FFF136Q36959855-8613D162-A80E-447A-BB4B-6B74BAB3CD4FQ37264464-F4D5C186-20D7-4A6A-A15A-04B086DE3C70Q37506507-4E551DEF-F9E2-4627-9F4C-64AD66400D3BQ38156760-385BAF77-EA8D-44D9-9D8D-7AFA0CC6A608Q38242091-FABFB12E-BB38-42B6-8050-388651262D6AQ38262418-F55A32E4-2A83-4B3E-9991-88038A369284Q38811387-71E24731-B271-444D-8E11-4B8DE5997499Q39906818-2541F01B-E6E4-4534-96CF-3AAAD7CD7589Q40299879-297FC672-8FD9-4E12-87FB-CE849E145825Q41009555-2996448F-5BB4-4FA3-8DF3-215B9CA636D2Q42121362-9944223A-8D33-4B23-A0D1-2723AE70F0F2Q42747563-17A1F8EB-0DF1-43BF-8009-F64085D77B45Q42922693-5EC3C7D8-56BC-4EAB-93D8-A19E3547DDCDQ43583632-CE288D1E-AC6A-4D80-8082-B3C72316C117Q43773506-D485FC68-233B-4FE4-80D5-5FBAE748BE95Q44060148-133DA265-1CCB-4AA9-86B2-A9536A2DEF68Q44345447-DAD7990B-0199-4D84-A19C-3891A99E70D9Q46280394-B60D1585-0416-4CB4-B0CF-D20F08416B04Q46976614-EECE30B4-DFB4-4CD1-ACB4-A31672833EC5
P2860
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@en
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@nl
type
label
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@en
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@nl
prefLabel
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@en
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@nl
P2093
P921
P356
P1433
P1476
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
@en
P2093
Del Dotto P
Verhagen Metman L
van den Munckhof P
P304
P356
10.1212/WNL.51.1.203
P407
P577
1998-07-01T00:00:00Z